Drug Profile
ABT 546
Alternative Names: A 216546; ABT-546Latest Information Update: 12 Feb 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 31 Dec 2012 Discontinued - Phase-I for Cardiovascular disorders in USA (unspecified route) before 2012
- 06 Mar 2003 No development reported - Phase-I for Cardiovascular disorders in USA (unspecified route)
- 06 Jun 2001 Phase-I clinical trials for Cardiovascular disorders in USA (Unknown route)